Progression of Early Atrophic Lesions in Age-related Macular degeneration
Progression of Early Atrophic Lesions in Age-related Macular degeneration
批准号:
10635325
负责人:
Monika Fleckenstein
金额:
$38.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2028-06-30
关键词:
AccelerationAddressAge related macular degenerationAngiographyAreaAtrophicBeliefBiological MarkersBlindnessCellsCessation of lifeClinicalClinical ResearchClinical Trials DesignColorDataData SetDepositionDevelopmentDiseaseDisease ProgressionEvaluationEyeFundusFutureImageImage AnalysisIndividualInterventionKineticsKnowledgeLearningLesionLocationManualsMeasuresModelingMonitorNonexudative age-related macular degenerationOptical Coherence TomographyOutcome MeasurePatient Outcomes AssessmentsPatientsPatternPerimetryPhenotypePredictive FactorPredispositionProbabilityPrognosisPrognostic FactorQuality of lifeQuestionnairesReadingResolutionRiskRisk FactorsRisk-Benefit AssessmentSample SizeScotomaSpeedStandardizationTestingTherapeuticTherapeutic EffectTherapeutic InterventionTimeTissuesTrainingTranslationsUnited States Food and Drug AdministrationVariantVisionVisual AcuityVisual FieldsVisual impairmentanalysis pipelineautomated segmentationclinically relevantdeep learningexperiencefundus imaginggenetic variantgeographic atrophyhigh riskimaging Segmentationinnovationinstrumentlongitudinal, prospective studyloss of functionluminancemultimodalitynew therapeutic targetnovelpatient prognosispatient safetypersonalized medicineprecision medicinepreventprimary outcomeprognosticprospectiveretinal imagingrisk varianttherapeutic targettooltransfer learningtrendtrial designvisual dysfunction
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY
We will focus on a previously largely under-explored but highly relevant time window in progression of
age-related macular degeneration (AMD), i.e., `early atrophic AMD'. We postulate that a therapeutic effect
in early atrophic AMD would probably save a large proportion of patients from progressive visual function loss
and that it seems more justifiable to risk interventions in this time window than in earlier AMD stages. Against
this background, a comprehensive knowledge of the natural disease progression in this potential
therapeutic margin is essential. We will implement innovative multimodal high-resolution retinal imaging,
comprehensive functional testing, and assessment of vision-related quality of life (VRQoL) combined with
standardized and exploratory analysis strategies in a prospective, longitudinal study. This will enable us to
characterize and quantify the microstructural changes and associated functional and VRQoL deficits in
eyes with early atrophic lesions with unprecedented accuracy. Knowledge of the strongest risk factors for
accelerated disease progression will allow identification of patients at highest risk for visual function loss.
Moreover, our hypothesis on disease-stage specific risk-factors may guide selection of therapeutic targets that
are particularly susceptible in early atrophic AMD. Tailoring therapeutics to specific phenotypes and disease
stages may be key to prevent irreversible vision loss and the associated reduced quality of life in patients with
AMD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Impact of Non-Exudative Type 1 Macular Neovascularization (MNV) on Age-related Macular Degeneration (AMD) Progression
-
批准号:10693953
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2022
-
负责人:Monika Fleckenstein
-
依托单位:
海外基金